A new 2025 Australian study has revealed that pregnancies achieved through In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) are at a higher risk of exposure to teratogenic medicines — drugs known to cause fetal harm or congenital defects during early development.
This discovery has raised serious attention in reproductive medicine because these exposures may partially explain the slightly higher rate of birth defects observed in some IVF-conceived babies compared to natural pregnancies.
Key Findings
- Conducted by University of South Australia and University of Western Australia (2025).
- The study examined thousands of pregnancies (both IVF and natural) and found:
- IVF/ICSI pregnancies had significantly higher rates of exposure to Category D and X medicines — drugs known to be potentially harmful to the fetus.
- The increased exposure mostly occurred during the first trimester, a critical period for organ formation.
- The findings were published in leading journals and summarized by News-Medical.net and UniSA Media Centre in early 2025.
What Are Teratogenic Medicines?
“Teratogens” are substances that can interfere with fetal development, leading to birth defects, miscarriage, or developmental disorders.
Common examples include:
- Isotretinoin (for acne) – causes severe birth defects.
- ACE inhibitors (for blood pressure) – linked to kidney and skull malformations.
- Anti-seizure medications (like Valproate) – risk of neural tube defects.
- Warfarin (blood thinner) – may cause fetal bleeding and skeletal abnormalities.
- Hormonal or fertility-support drugs used during IVF cycles, if continued in early pregnancy, may influence fetal development.
Possible Reasons for Increased Exposure in IVF
-
Medication Overlap During IVF Treatment
- Women undergoing IVF often take multiple hormonal and support drugs such as progesterone, estrogen, and immune modulators.
- Some of these medicines may continue into early pregnancy, increasing the exposure window.
-
More Medical Interventions
- IVF pregnancies are often closely monitored and involve more medical treatments compared to spontaneous pregnancies.
-
Older Maternal Age or Coexisting Health Conditions
- Many IVF patients have hypertension, diabetes, thyroid, or autoimmune diseases, requiring medication — some of which can be teratogenic.
-
Lack of Early Pregnancy Recognition
- Early continuation of fertility medications before confirming pregnancy can lead to unintentional teratogenic exposure.
Potential Effects on the Baby
Exposure to teratogenic medicines during early pregnancy can lead to:
- Congenital heart defects
- Neural tube defects (spina bifida)
- Cleft lip or palate
- Skeletal and limb malformations
- Growth retardation or stillbirth (in severe cases)
Prevention and Safety Measures
- Pre-IVF medication review – every woman should have her current medicines checked for fetal safety.
- Switch to safer alternatives under doctor supervision before IVF.
- Early pregnancy confirmation to stop or adjust risky medicines immediately.
- Consult with reproductive and obstetric pharmacologists if chronic medication use is necessary.
- Avoid self-medication, supplements, or over-the-counter drugs without medical advice.
- Continuous prenatal monitoring through scans and biochemical tests for early detection of anomalies.
Expert Insights
- Researchers emphasize that the goal is not to alarm IVF patients, but to improve medication management and awareness.
- Most IVF pregnancies still result in healthy babies, but early medical vigilance can prevent potential defects.
- The findings highlight a modifiable risk factor — meaning careful drug management can directly lower birth-defect risks.
Conclusion
The discovery of higher teratogenic medicine exposure in IVF/ART pregnancies is a vital step toward safer reproductive practices.
By combining responsible prescribing, patient awareness, and strict medical supervision, IVF can remain both safe and successful, ensuring healthier outcomes for mothers and babies alike.